Biopharma

View All

multiple myeloma
The changing landscape of Multiple Myeloma therapies market

Multiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due to the presence of malignant plasma cells in bone marrow. Due to the vigorous proliferation of highly abnormal, unstable cells circulating via the bloodstream and lymph nodes, ...

Find More

Novo Nordisk
China Preparing for Pharma Big Bang: Is this Alarm Bell for US, Euro Pharma Giants?

As part of its “Made in China 2025” industrial plan, China hopes to reinvent its pharmaceutical industry. President Xi Jinping has identified his country’s reliance on foreign drug imports as a critical concern. China’s enormous population, coupled with the rise of disease and illness, make the country a prime marke...

Find More